Back

Real-world evidence on pulmonary arterial hypertension: interim analysis from the Italian observational study INSPECTIO

1 September 2024 (17:00 - 17:50)
Organised by: Logo
Congress Presentation Part of: Pulmonary hypertension: insights from registries, retrospective data sets, and meta-analyses Pulmonary Hypertension ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Professor Michele D'Alto

AORN Ospedali dei Colli - Monaldi Hospital, Naples (Italy)

7 More presentations in this session

Presentation thumbnail
Improving morbidity and mortality in patients with pulmonary hypertension: insights from a nation-wide registry
Professor C. Kaymaz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
Idiopathic pulmonary arterial hypertension, associated with connective tissue disease and comorbidities: prognostic differences? Results the Spanish Registry of pulmonary hypertension (REHAP Registry)
Doctor R. Bravo-Marques (Marbella, ES)
Abstract Slides Video
Presentation thumbnail
Clinical, echocardiographic and haemodynamic predictors of morbidity and mortality in pulmonary hypertension: a nation-wide registry
Professor C. Kaymaz (Istanbul, TR)
Abstract Slides Video
Presentation thumbnail
The importance of comorbidities in idiopathic and associated with connective tissue disease pulmonary arterial hypertension: from the Spanish Registry of Pulmonary Hypertension (REHAP Registry)
Doctor R. Bravo-Marques (Marbella, ES)
Abstract Slides Video
Presentation thumbnail
A systematic review and meta-analysis of health-related quality of life (HRQoL) outcomes in randomised controlled trials for pulmonary arterial hypertension (PAH)
Doctor F. Varian (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Pulmonary hypertension: insights from registries, retrospective data sets, and meta-analyses

The Event

Event poster

ESC Congress 2024

1 September 2024 17:00 CET
You may be interested in
thumbnail
Congress Presentation
Safety and efficacy of macitentan and riociguat upfront combination therapy in patients with idiopathic pulmonary arterial hypertension at intermediate risk.
thumbnail
Congress Presentation
Efficacy and tolerability of triple sequential combination therapies with selexipag in patients with pulmonary arterial hypertension : insights from a single-centre study
thumbnail
Congress Presentation
Representativeness of randomized clinical trial criteria among the real-world patients with pulmonary arterial hypertension: an analysis from the FOCUS-PAH registry

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources